LuciAlpe 150 mg Tablet

Molecule: Alpelisib

Strength: 150 mg

Quantity: 28 Tablets

Form: Tablet

Packaging Type: Bottle

Manufacturer/Marketed By: Lucius Pharma

Country of Origin: Laos

Description

Introducing LuciAlpe (Alpelisib), a revolutionary kinase inhibitor explicitly designed for the treatment of advanced or metastatic breast cancer. Each tablet contains 150 mg of Alpelisib, expertly formulated to target PIK3CA mutations, providing a precise approach for those battling hormone receptor (HR)-positive, HER2-negative breast cancer. Indicated for postmenopausal women and men, LuciAlpe is to be used in combination with Fulvestrant. This powerful solution offers a confident step towards improved outcomes in cancer treatment for patients who have progressed on or after an endocrine-based regimen. Experience LuciAlpe's targeted efficacy and empower your journey against breast cancer. Remember that combining it with LuciAnam (Anamorelin) can enhance your therapeutic protocol.